Previously, the expression of POU2F3 was observed only in 15∼20% of SCLC cases, 70% of thymic squamous cell carcinoma cases and castration-resistant prostate adenocarcinoma (CRPC) cases [12]. This evidence concerns the gene POU2F3 and thymus squamous cell carcinoma.